Trial of vaccine for triple-negative breast cancer yields ‘encouraging’ results
Nearly 75% of women treated with a novel vaccine designed to prevent triple-negative breast cancer achieved an immune response, according to updated results of a phase 1 trial.Injection site reactions accounted for all dose-limiting toxicities, findings presented at SITC Annual Meeting showed.